National Repository of Grey Literature 1 records found  Search took 0.00 seconds. 
Extracorporeal Elimination of Circulating Pegylated Liposomal Doxorubicin to Enhance the Benefit of Cytostatic Therapy in Ovarian Cancer
Kubeček, Ondřej ; Filip, Stanislav (advisor) ; Mohelníková Duchoňová, Beatrice (referee) ; Demlová, Regina (referee)
Extracorporeal elimination of circulating pegylated liposomal doxorubicin to enhance the benefit of cytostatic therapy in ovarian cancer Background: Encapsulation of cytotoxic drugs into liposomes changes their pharmacokinetic and toxicologic properties in order to enhance the benefit of chemotherapy. Pegylated liposomal doxo- rubicin (PLD) is one of the most prominent drugs in this group. Despite its reduced cardio- and hematologic toxicity, it confers a higher risk of mucocutaneous toxicity in comparison to its parent drug (i.e. doxorubicin, DOX). The specific pharmacokinetic properties of PLD enable its partial elimination from plasma after reaching maximum concentration within the tumor tissue in order to reduce its toxicity. Aim: This doctoral thesis evaluates the efficacy and safety of plasmafiltration (PF) as a me- thod of extracorporeal PLD elimination, seeking to enhance its therapeutical benefit. The reduc- tion of PLD-related toxicity thanks to the application of PF was determined. Further, PLD pharmacokinetics and the factors affecting it, as well as the effect of PF on the outcome of cancer therapy, were also analyzed. Material and methods: Sixteen patients with platinum-resistant epithelial ovarian cancer were enrolled in the study. PLD was administered as a one-hour i.v. infusion of...

Interested in being notified about new results for this query?
Subscribe to the RSS feed.